Overview

Pharmacokinetic Study of Ondansetron Administered as IR (Zofran) and MR (EUR1025)

Status:
Completed
Trial end date:
2009-04-01
Target enrollment:
Participant gender:
Summary
The objective of the study is to assess blood levels of ondansetron (EUR1025 24 mg) dose and Zofran 8 mg dose after single and multiple doses are given when taken with a meal and taken on an empty stomach.
Phase:
Phase 1
Details
Lead Sponsor:
Forest Laboratories
Treatments:
Ondansetron